stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) EV/EBITDA
Amylyx Pharmaceuticals, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 31.6× (February 2024) — the current reading is the lowest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 21.3× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | (95.44%) |
| Jun 2024 | 1.0× | (54.06%) |
| Mar 2024 | 2.1× | (90.14%) |
| 7 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | n/m |
| PRGO Perrigo Company plc compare | n/m |
| AMLX Amylyx Pharmaceuticals, Inc. | n/m |
| TRLV Trulieve Cannabis Corp. compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.4× |
| RGC Regencell Bioscience Holdings Limited compare | 1.1× |
| SUPN Indivior Pharmaceuticals Inc. compare | 7.0× |
| PBH Prestige Consumer Healthcare Inc. compare | 12.4× |
| LQDA Liquidia Corporation compare | 22.7× |
| Drug Manufacturers Specialty & Generic industry median | 12.2× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement